Could the daunting biology of small-cell lung cancer provide the key to elucidating drug resistance?
At ELCC 2021, Prof. Fiona Blackhall sees hope for improving patients’ poor prognoses on the horizon
The “holy grail” of lung cancer research: bring the immune system into every tumour
With multiple new therapies available, Prof. Johan Vansteenkiste says the search is on for biomarkers to better match patients to treatments
What should oncologists know about e-cigarettes?
Electronic nicotine delivery systems (ENDS) are battery-powered products that create an aerosol by heating a liquid consisting of propylene glycol and vegetable glycerin and flavouring agents. The liquid may or may not (but usually does) contain nicotine, at variable doses. Differently from conventional cigarettes, there is no combustion of tobacco in ENDS, thus making people think they cause less harm. However, the varying voltage that is applied to the liquid creates a mixture of potentially toxic substances in the aerosols that are then inhaled by users.
Immunotherapy fails to improve PFS and OS in relapsed mesothelioma
Results from the PROMISE-meso trial presented
Is tissue tumour mutational burden a predictive biomarker for immunotherapy in lung cancer?
Two post-hoc analyses of KEYNOTE studies presented at ESMO 2019
Anlotinib improves overall survival in relapsed SCLC
Results of ALTER 1202 reveal survival benefit for anlotinib third-line in small-cell lung cancer
Ceritinib demonstrates efficacy in brain metastases in ALK+ NSCLC
Results from ASCEND-7 trial confirms the place of ceritinib as a standard treatment option for patients with ALK+ non-small-cell lung cancer and active brain metastases